Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipidology, Volume 17, Issue 3, May–June 2023, Pages 342–355] (Journal of Clinical Lipidology (2023) 17(3) (342–355), (S193328742300065X), (10.1016/j.jacl.2023.03.007))

Joseph L. Witztum; Daniel Gaudet; Marcello Arca; Alan Jones; Handrean Soran; Ioanna Gouni-Berthold; Erik S. G. Stroes; Veronica J. Alexander; Richard Jones; Lynnetta Watts; Shuting Xia; Sotirios Tsimikas

doi:10.1016/j.jacl.2023.09.010

Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipidology, Volume 17, Issue 3, May–June 2023, Pages 342–355] (Journal of Clinical Lipidology (2023) 17(3) (342–355), (S193328742300065X), (10.1016/j.jacl.2023.03.007))

Joseph L. Witztum
, Daniel Gaudet
, Marcello Arca
, Alan Jones
, Handrean Soran
, Ioanna Gouni-Berthold
, Erik S. G. Stroes
, Veronica J. Alexander
, Richard Jones
, Lynnetta Watts
, Shuting Xia
, Sotirios Tsimikas

University of California at San Diego
University of Montreal
University of Rome La Sapienza
University Hospitals Birmingham NHS Foundation Trust
Department of Haematology, Manchester Royal Infirmary, Manchester, M13 9WL, UK;
Center for Biochemistry, Faculty of Medicine, University of Cologne, Cologne, Germany
Ionis Pharmaceuticals
Akcea Therapeutics

Research output: Contribution to journal › Comment/Letter to the editor › Academic

25 Downloads (Pure)

Abstract

The authors regret that the error bars in Figure 5 were inaccurately rendered in the original publication. The corrected data representations for Figure 5 are provided below. The authors apologize for any inconvenience that resulted from this oversight.

Original language	English
Pages (from-to)	e482-e483
Journal	Journal of clinical lipidology
Volume	18
Issue number	3
Early online date	2024
DOIs	https://doi.org/10.1016/j.jacl.2023.09.010
Publication status	Published - 1 May 2024

Access to Document

10.1016/j.jacl.2023.09.010

Corrigendum-to-volanesorsen-and-triglyceride-levels-in-familial-chylomicronemia-syndrome.pdfFinal published version, 244 KBLicence: CC BY

Fingerprint

Dive into the research topics of 'Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipidology, Volume 17, Issue 3, May–June 2023, Pages 342–355] (Journal of Clinical Lipidology (2023) 17(3) (342–355), (S193328742300065X), (10.1016/j.jacl.2023.03.007))'. Together they form a unique fingerprint.

Cite this

Witztum, J. L., Gaudet, D., Arca, M., Jones, A., Soran, H., Gouni-Berthold, I., Stroes, E. S. G., Alexander, V. J., Jones, R., Watts, L., Xia, S., & Tsimikas, S. (2024). Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipidology, Volume 17, Issue 3, May–June 2023, Pages 342–355] (Journal of Clinical Lipidology (2023) 17(3) (342–355), (S193328742300065X), (10.1016/j.jacl.2023.03.007)). Journal of clinical lipidology, 18(3), e482-e483. https://doi.org/10.1016/j.jacl.2023.09.010

Witztum, Joseph L. ; Gaudet, Daniel ; Arca, Marcello et al. / Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome : Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipidology, Volume 17, Issue 3, May–June 2023, Pages 342–355] (Journal of Clinical Lipidology (2023) 17(3) (342–355), (S193328742300065X), (10.1016/j.jacl.2023.03.007)). In: Journal of clinical lipidology. 2024 ; Vol. 18, No. 3. pp. e482-e483.

@article{7a0b507cea174d17bc794e8309f71005,

title = "Corrigendum to {\textquotedblleft}Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial{\textquotedblright} [Journal of Clinical Lipidology, Volume 17, Issue 3, May{\textendash}June 2023, Pages 342{\textendash}355] (Journal of Clinical Lipidology (2023) 17(3) (342{\textendash}355), (S193328742300065X), (10.1016/j.jacl.2023.03.007))",

abstract = "The authors regret that the error bars in Figure 5 were inaccurately rendered in the original publication. The corrected data representations for Figure 5 are provided below. The authors apologize for any inconvenience that resulted from this oversight.",

author = "Witztum, \{Joseph L.\} and Daniel Gaudet and Marcello Arca and Alan Jones and Handrean Soran and Ioanna Gouni-Berthold and Stroes, \{Erik S. G.\} and Alexander, \{Veronica J.\} and Richard Jones and Lynnetta Watts and Shuting Xia and Sotirios Tsimikas",

note = "Publisher Copyright: {\textcopyright} 2024",

year = "2024",

month = may,

day = "1",

doi = "10.1016/j.jacl.2023.09.010",

language = "English",

volume = "18",

pages = "e482--e483",

journal = "Journal of clinical lipidology",

issn = "1933-2874",

publisher = "Elsevier BV",

number = "3",

}

Witztum, JL, Gaudet, D, Arca, M, Jones, A, Soran, H, Gouni-Berthold, I, Stroes, ESG, Alexander, VJ, Jones, R, Watts, L, Xia, S & Tsimikas, S 2024, 'Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipidology, Volume 17, Issue 3, May–June 2023, Pages 342–355] (Journal of Clinical Lipidology (2023) 17(3) (342–355), (S193328742300065X), (10.1016/j.jacl.2023.03.007))', Journal of clinical lipidology, vol. 18, no. 3, pp. e482-e483. https://doi.org/10.1016/j.jacl.2023.09.010

Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipidology, Volume 17, Issue 3, May–June 2023, Pages 342–355] (Journal of Clinical Lipidology (2023) 17(3) (342–355), (S193328742300065X), (10.1016/j.jacl.2023.03.007)). / Witztum, Joseph L.; Gaudet, Daniel; Arca, Marcello et al.
In: Journal of clinical lipidology, Vol. 18, No. 3, 01.05.2024, p. e482-e483.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome

T2 - Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipidology, Volume 17, Issue 3, May–June 2023, Pages 342–355] (Journal of Clinical Lipidology (2023) 17(3) (342–355), (S193328742300065X), (10.1016/j.jacl.2023.03.007))

AU - Witztum, Joseph L.

AU - Gaudet, Daniel

AU - Arca, Marcello

AU - Jones, Alan

AU - Soran, Handrean

AU - Gouni-Berthold, Ioanna

AU - Stroes, Erik S. G.

AU - Alexander, Veronica J.

AU - Jones, Richard

AU - Watts, Lynnetta

AU - Xia, Shuting

AU - Tsimikas, Sotirios

PY - 2024/5/1

Y1 - 2024/5/1

N2 - The authors regret that the error bars in Figure 5 were inaccurately rendered in the original publication. The corrected data representations for Figure 5 are provided below. The authors apologize for any inconvenience that resulted from this oversight.

AB - The authors regret that the error bars in Figure 5 were inaccurately rendered in the original publication. The corrected data representations for Figure 5 are provided below. The authors apologize for any inconvenience that resulted from this oversight.

UR - https://www.scopus.com/pages/publications/85189550492

U2 - 10.1016/j.jacl.2023.09.010

DO - 10.1016/j.jacl.2023.09.010

M3 - Comment/Letter to the editor

C2 - 38565460

SN - 1933-2874

VL - 18

SP - e482-e483

JO - Journal of clinical lipidology

JF - Journal of clinical lipidology

IS - 3

ER -

Witztum JL, Gaudet D, Arca M, Jones A, Soran H, Gouni-Berthold I et al. Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipidology, Volume 17, Issue 3, May–June 2023, Pages 342–355] (Journal of Clinical Lipidology (2023) 17(3) (342–355), (S193328742300065X), (10.1016/j.jacl.2023.03.007)). Journal of clinical lipidology. 2024 May 1;18(3):e482-e483. Epub 2024. doi: 10.1016/j.jacl.2023.09.010

Abstract

Access to Document

Other files and links

Fingerprint

Cite this